塞库金单抗
普雷沃菌属
微生物群
强直性脊柱炎
医学
代谢组学
肠道菌群
拟杆菌
蔷薇花
人口
免疫学
疾病
生物信息学
生物
内科学
细菌
遗传学
环境卫生
银屑病性关节炎
作者
Chao Sun,Yuyan Chao,Haojie Xu,X D Yang,Lijia Pei,Guixia Xu,Fei Wang,Xiaoyun Fan,Lin Tang,Changhao Xie,Yin Su,Xin Wang
标识
DOI:10.1111/1756-185x.15218
摘要
Abstract Objective Alterations in gut microbiota have been implicated in the pathogenesis of ankylosing spondylitis (AS), but the underlying mechanisms remain elusive. This study aims to investigate changes in gut microbiota and metabolites in individuals with AS before and after treatment with secukinumab, to identify the biological characteristics specific to AS patients and investigate the potential biomarkers, for optimizing therapeutic strategies more effectively. Methods Fecal microbiome data were collected from 30 AS patients before and after secukinumab therapy and compared with data from 40 healthy controls (HC). Additionally, we analyzed the metabolic profile of both groups from plasma. Results Findings indicated that the treatment‐induced changes in the composition of several crucial bacterial groups, including Megamonas , Prevotella_9 , Faecalibacterium , Roseburia , Bacteroides , and Agathobacter . Post‐treatment, these groups exhibited a distribution more akin to that of the healthy populations compared with their pretreatment status. We identified three gut microbial taxa, namely Prevotellaceae_bacterium_Marseille_P2831 , Prevotella_buccae , and Elusimicrobiota , as potential biomarkers for diagnosing individuals at a higher risk of developing AS and assessing disease outcomes. Plasma metabolomics analysis revealed 479 distinct metabolites and highlighted three disrupted metabolic pathways. Integration of microbiome and metabolomics datasets demonstrated a significant degree of correlation, underscoring the impact of the microbiome on metabolic activity. Conclusion Secukinumab can restore the balance of the gut microbiome and metabolites in AS patients, rendering them more similar to those found in the healthy population. The analysis of microbiome and metabolomics data have unveiled some candidate biomarkers capable of evaluating treatment efficacy.
科研通智能强力驱动
Strongly Powered by AbleSci AI